Germany’s MorphoSys (FSE: MOR) and Belgium’s Galapagos (Euronext: GLPG) today announced the end of the clinical development program of MOR106 in atopic dermatitis.
The joint decision of all three involved parties, Galapagos, MorphoSys and Novartis (NOVN: DE), was based on an interim analysis for futility that was performed in the Phase II GUANA trial. The analysis detected a low probability to meet the primary endpoint of the study, defined as the percentage change in the eczema area and severity index (EASI) score. The decision was based on a lack of efficacy and not on safety concerns.
Despite the announcement, MorphoSys shares were up more than 2% at 97.05 euros, and Galapagos gained 1.97% to 162.85 euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze